FUNDING SUMMARY
• 29 grants, total funding: $9,197,682
• As nominated principal applicant or principal applicant: $854,766
• External Agencies (CIHR/Kidney Foundation of Canada/AHRQ/PSI): $7,802,202
FUNDING DETAILS
29 Pragmatic Randomized Trial of High or Standard Phosphate Targets in ESKD (PHOSPHATE) Canadian Institutes of Health Research Co-Investigator [PI Ron Wald, Toron-to] July 2025 to June 2029
C$ 1,526,176
28 Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (GUARD-1) Canadian Institutes of Health Research Co-Investigator [PI Ron Wald, Toron-to] July 2025 to June 2028
C$566,099
27 Albumin To Enhance Recovery after severe Acute Kidney Injury (ALTER-AKI): a multicentre randomized controlled trial. Canadian Institutes of Health Research Co-investigator
[PI: Edward Clark] July 2024 to June 2027, C$956,249
26 Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (GUARD-1) Canadian Institutes of Health Research Co-Investigator [PI Ron Wald, Toronto] July 2024 to June 2027, C$566,099
25 Albumin to Enhance Recovery from Severe Acute Kidney Injury Kidney Foundation of Canada Co-investigator
[PI: Edward Clark] Oct 2021 to March 2023
C$100,000
24 Albumin to Enhance Recovery from Severe Acute Kidney Injury: A Multi-Centre Pilot Trial (ALTER-AKI) Physicians Services Incorporated Co-investigator
[PI: Edward Clark] Oct 2021 to Sep 2024
C$300,000
23 Albumin to Prevent Hypotension and Enhance Recovery from Severe Acute Kidney Injury Treated with Renal Replacement Therapy: A Proof-of-Concept Study The Ottawa Hospital Academic Medical Organization Co-investigator
[PI: Edward Clark] March 2020 to March 2022; C$98,400
22 Exploring the Relationship Between Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients Department of Medicine, University of Ottawa Co-investigator
[PI: Edward Clark] July 2020 to June 2022; C$48,000
21 Individualizing the hemodialysis access strategy: addressing knowledge gaps to promote shared decision-making Kidney Foundation of Canada Co-Investigator [PI Pietro Ravani, Calgary] July 2019 to June 2021
C$ 100,000
20 Individualizing the hemodialysis access strategy: addressing knowledge gaps to promote shared decision-making Canadian Institutes of Health Research Co-Investigator [PI Pietro Ravani, Calgary] July 2019 to June 2022
C$ 677,025
19 Predicting renal recovery in patients requiring outpatient dialysis after acute kidney injury (RECOVER AKI) Ontario Renal Network Co-investigator
[PI: Edward Clark] July 2018 to June 2019, C$147,230
18 Diet or Additional Supplement to Increase Potassium Intake: An Adaptive Clinical Trial Hecht Foundation Nominated Principal Applicant July 2018 to June 2021; C$286,540
17 Predicting Renal Recovery from Dialysis-Requiring Acute Kidney Injury at Time of Hospital Discharge Department of Medicine, University of Ottawa, IQ@TOH Co-investigator
[PI: Edward Clark] Nov 2017 to Nov 2018; C$20,000
16 Saline versus albumin fluid for extracorporeal removal with slow low efficiency dialysis Department of Medicine, University of Ottawa Principal Investigator
[nominated PI: Edward Clark] July 2017 to June 2019; C$47,988
15 Blood Pressure Measurement: Should technique Define Targets? Physician Services Incorporated Principal Investigator [nominated PI Marcel Ruzicka] August 2017 to July 2018; C$45,000
14 What is the Evidence Behind the Recommendation of Withholding Certain Medications before Contrast Procedures? A Systematic review of the Evidence Canadian Institutes of Health Research Nominated Principal Applicant July 2016 to June 2017
C$ 99,000
13 The ACCESS trial: A Randomized trial comparing Catheters to Fistula in Elderly Patients starting Dialysis Canadian Institutes of Health Research co-Investigator [PI: Dr Rob Quinn, Calgary] Sep 2015 - Feb 2018
C$ 513,898
12 Standard versus Accelerated Initaition of Renal Replacement Therapy (STARRT-AKI) Canadian Institutes of Health Research co-Investigator [PI: Dr Ron Wald, Toronto] Sep 2015 - Aug 2019
C$1,608,548
11 Protein Supplementation for Thiazide-diuretic induced hyponatremia: A Pilot Study’ The Ottawa Hospital Academic Medical Organization Principal Investigator [nominated PI Marcel Ruzicka] July 2015 to June 2018
C$89,998
10 Assessment of Effectiveness of Counselling by a Registered Dietician on Low Salt Diet in Patients with Hypertension: A Pragmatic Clinical Trial The Ottawa Hospital Academic Medical Organization Principal Investigator [nominated PI Marcel Ruzicka] July 2014 to June 2017
C$95,055
9 The Prevention of Acute Kidney Injury after Contrast-Enhanced Computed Tomography: A Pilot trial of Oral Fluid versus Intravenous Saline Department of Medicine, University of Ottawa Nominated Principal Investigator July 2013 to June 2016
C$114,775
8 Antimicrobial pharmacokinetics in critically ill adults during sustained low efficiency dialysis Kidney Foundation of Canada co-Investigator [PI: Dr Salmaan Kanji] July 2014 - June 2016
C$100,000
7 Standard versus Accelerated Initiation of Renal Replacement Therapy (STARRT-AKI): Pilot Trial Canadian Institutes of Health Research co-Investigator [PI: Dr Ron Wald, Toronto] Sep 2014 - Aug 2019
C$220,996
6 Reducing the Risk of serious adverse events and improving quality of life for patients with kidney disease: the role of arteriovenous fistula creation in dialysis Canadian Institutes of Health Research co-Investigator [PI: Dr Rob Quinn, Calgary] March 2013 - Feb 2015
C$152,879
5 Curcumin to Prevent Peri-operative Complications after Elective Abdominal Aortic Aneurysm Repair. Canadian Institutes of Health Research co-Investigator [PI: Dr Amit Garg, London] Oct 2010 - Oct 2014
C$328,530]
4 E-health Interventions to Improve Vascular Health in Workplaces: Foundational Research Examining Physical Activity Among Nurses Working in Hospitals University of Ottawa Heart Institute co-Investigator [PI: Dr Bob Reid] May 2014 - May 2015
C$ 50,000
3 Troponin Cardiac Marker Interpretation During Renal Function Impairment Agency for Healthcare Research and Quality co-Investigator [PI: Mohammed Ansari] 2009
$162,699
2 Centre for Excellence for Treatment of Resistant Hypertension: Establishment Evaluation of Efficacy, Mechanisms and Safety of Renal Sympathetic Denervation The Ottawa Hospital Academic Medical Organization co-Investigator [PI: Dr Ruzicka] July 2014 - June 2017
C$99,998
1 Cost-Effectiveness of Visipaque in patients with Renal Insufficiency GE Healthcare (Industry) co-PI [PI Ben Chow, Heart Institute] June 2012- June 2015;
C$ 76,500
